Introduction: Malignant pleural mesothelioma (MPM) is an aggressive tumor strongly associated with asbestos exposure. Patients are usually diagnosed when current treatments have limited benefits, highlighting the need for noninvasive early diagnostic tests to monitor asbestos-exposed people.
Introduction
Malignant pleural mesothelioma (MPM) is an aggressive tumor strongly associated with asbestos exposure. It occurs long after the first exposure, with risk increasing depending on duration and intensity of exposure. 1 MPM incidence dramatically increased as a result of widespread use of asbestos in the past decades. Banning occupational asbestos use and preventing environmental asbestos exposure is regarded as the only effective strategy to hinder MPM occurrence. However, for subjects who underwent environmental or occupational asbestos exposure in the past there is no preventive measure currently available, except for continuous monitoring aiming at an early MPM diagnosis which might improve life expectancy. Patients are usually diagnosed in an advanced phase when radical surgery cannot be performed, and the effectiveness of current cytotoxic therapies is limited, highlighting an urgent need for sensitive noninvasive tests for early MPM diagnosis. 2 In recent years, there is a growing interest in DNA methylation (DNAm) profile changes as possible diagnostic/prognostic biomarkers in cancer research. 3 DNAm is stable, yet it may be modified across a lifetime by several factors including lifestyle, environmental exposures, ageing, and diseases, and is thus regarded as an adaptive phenomenon potentially linking environmental factors and development of disease phenotypes. 4 Being an early event in tumor development, aberrant DNAm has been suggested as a tool for early cancer detection and prognosis, and DNAm changes are regarded as possible actors also in MPM development and progression. 5, 6 Along this line, we sought to determine whether white blood cell (WBC) DNAm profiles might associate with MPM occurrence in subjects with asbestos exposure, considering that tumor environment in the pleura may trigger molecular changes in perfusing WBCs.
We thus investigated the occurrence of differences in the DNAm profiles in a large series of MPM cases and asbestos-exposed controls, all of them with quantitative assessment of asbestos exposure.
Materials and Methods

Study Population and Asbestos Exposure Assessment
Study subjects belong to a wider ongoing collaborative study on MPM already described in previous reports. [7] [8] [9] Details on study population are provided in the Supplementary Methods. Briefly, cases and controls were enrolled either in the municipalities of Casale Monferrato (Piedmont region, Italy), an area with high occupational and environmental asbestos exposure, or Turin (Piedmont, Italy).
Cases were enrolled in the main hospitals of the reference centers after histologic confirmation of MPM diagnosis. Controls were randomly selected from the local population (Casale Monferrato study), or among subjects not affected by neoplastic or respiratory conditions admitted to general medicine or urology units at the reference hospital (Turin study). 7, 8 For all the subjects, cumulative asbestos exposure was quantitatively assessed as described in Ferrante et al. 10 Briefly, occupational history and lifestyle habit information was collected through intervieweradministered questionnaires filled out at enrollment during a face-to-face interview. An occupational epidemiologist assessed probability, frequency, intensity, and duration of asbestos exposure (method detailed in Ferrante et al. 10 ) for both occupational and nonoccupational exposures, considering their occupational and residential history and other possible circumstances of asbestos exposure, such as sharing a home with an asbestos worker.
In total, 300 samples (163 MPM cases and 137 non-MPM controls) were included in this study and underwent DNAm analysis.
Our study complies with the Declaration of Helsinki principles, and conforms to ethical requirements. All volunteers signed an informed consent form at enrollment. The study protocol was approved by the Ethics Committee of the Italian Institute for Genomic Medicine (formerly Human Genetics Foundation, Turin, Italy).
HumanMethylation450 BeadChip (Illumina, San Diego, California). The percentage of methylation at each cytosine-guanine dinucleotide (CpG) site (methylation beta value), ranging from 0 for no methylation, to 1 for full methylation, was assessed for each subject. Laboratory methods for DNA extraction, BeadChip processing, methylation levels measurement, and data quality controls are detailed in the Supplementary Methods.
Statistical Methods
Study design is outlined in Supplementary Figure 1 . All statistical analyses were conducted using the open source software Rv3.4.0.
11 Subjects were randomly allocated (R function split) to two analytical sets: a training set of 82 MPM cases and 68 controls (discovery panel), and a test set of 81 cases and 69 controls (replication panel).
Possible differences between the two sets were checked for sex, age, center, exposure, tumor histotype, smoking habits, and WBC estimated percentages. The same comparison was performed for descriptive purposes within each one of the two sets (Table 1) .
Epigenome-wide differential methylation between cases and controls was tested by regression models described below both at single CpG and at the regional level. For all the regression analyses, continuous variables such as age (years), and asbestos exposure doses (fibers/mL-years), were rank transformed (R function rntransform) to remove skewness.
WBC subtype percentages from genome-wide methylation data for each subject were estimated to evaluate differences in WBC profiles between cases and controls. 12 However, since numeric changes and functional dysregulation of immunocompetent cells triggered by asbestos and linked to MPM etiopathogenesis have been reported in the literature (Table 2) , regression analyses were not adjusted by WBC composition (see Discussion section). [13] [14] [15] [16] [17] [18] [19] Potential population stratification was taken into account by including in the regression analyses the first two principal components (SNP_PCs1-2) calculated on the basis of our previous genome-wide genotyping study 9 (Supplementary Methods); batch and technical effects correction was performed adjusting for BeadChip control probes PCs1-10 (CTR_Probes_PCs1-10; Supplementary Methods). Before inclusion as covariates into regression analyses, SNP_PCs1-2 and CTR_Probes_PCs1-10 variables were rank transformed (R function rntransform). For multiple comparisons, Benjamini-Hochberg false discovery rate p (p fdr ) 0.05 was considered statistically significant.
Single CpG Analysis
Cases versus controls differential methylation (DMe) at single-CpGs was tested in the training set by generalized linear models (GLM) analysis adjusted for asbestos exposure, sex, age, population stratification, and technical variability, as described above.
Smoking habit was purposely not added to our multivariate statistical model because smoking is not among the known risk factors for mesothelioma. However, because smoking habits may modify DNAm profiles at some genomic locations, its effect on methylation levels was targetedly investigated on CpGs that were differentially methylated between cases and controls.
To ensure a power of the study greater than 90% (two-tailed test, 0.05 alpha error), only CpGs with regression effect size differences between cases and controls !j0.1j were considered in the discovery phase on the training set, and subsequently investigated in the test set under the same analytical conditions. CpGs with effect size differences between cases and controls !j0.1j and p fdr 0.05 in both the training and test sets were considered as replicating, and underwent gene set enrichment analysis. 20 Additionally, test set subjects were clustered (unsupervised clustering analysis, R package Rgplots) according to their methylation levels of the differentially methylated single-CpGs (DM-CpGs). For this analysis, samples with missing methylation beta values for any of the CpGs were removed.
Finally, in the test set, we compared the area under the receiver operating characteristic curve (AUC) of two models by the DeLong test: model 1 included age, sex, and asbestos exposure; and model 2 was as model 1 plus methylation levels of significant and replicating DM-CpGs. This was done to test the potential improvement in casecontrol discrimination when considering DMe information together with asbestos exposure information.
Regional Differential Methylation Analysis
We used the A-clustering algorithm to define genomic regions characterized by a group of two or more neighboring CpGs (CpG clusters) with correlated methylation levels (Supplementary Methods) under the hypothesis that methylation changes in genomic regions Table 2 . Reports of Asbestos-Induced Potential Immune System Deregulation Observation Source
Asbestos exposure is associated with autoimmune response Pfau et al. 13 Possible relationship between immunological pathways and processes leading to asbestos-related diseases Noonan et al. 14 Asbestos and asbestos-related inflammation may modify cellular and molecular features of immunocompetent cells eventually leading to reduction of tumor immunity Matsuzaki et al. 15 Significant reduction in surface expression levels of NK-cell specific activating receptors in NK cell line YT-A1 exposed to chrysotile asbestos Nishimura et al. 16 Reduction of the intracellular serine protease granzyme A secreted by NK cells against tumor cells Nishimura et al. 17 Reduction of degranulation events Maeda et al. 18 MT-2 cells (human T-lymphocyte immortalized polyclonal T-lymphocyte line) exposed to short-term high dose of chrysotile asbestos showed apoptosis, ROS production, activation of the mitochondrial apoptotic pathway, similar to what found in alveolar epithelial and pleural mesothelial cells exposed in vitro to asbestos Maeda et al. 18 Long-term low-dose exposure of the same cell line showed resistance to asbestos, long-term survival, and T-lymphocyte Vb receptors activation, suggesting an asbestos-related super-antigenic activity in human T-lymphocytes Miura et al.
19
A particular fraction of CD4þ T lymphocytes acquires apoptosis resistance through activation of STAT3 and transcriptional activation of bcl-2, after direct interaction with asbestos fibers CD4þ T lymphocytes from asbestosis patients without signs of a malignant tumor showed relative expression of bcl-2 similar to that of healthy donors Miura et al.
CD4þ T lymphocytes from malignant mesothelioma patients exhibited significant up-regulation of bcl-2 expression, suggesting the onset of MPM might be related to the enhanced survival of a specific population of CD4þT lymphocytes NK, natural killer; MPM, malignant pleural mesothelioma.
may underlie potential functional changes linked to MPM. In the training set, we tested the occurrence of differentially methylated regions (DMRs) between cases and controls by generalized estimating equations with the same adjustments as the single-CpG analysis. DMRs with effect size differences of at least 0.1 between cases and controls were investigated for occurrence of DMe in the test set under the same analytical conditions. DMRs replicating in the test set (i.e., effect sizes !j0.1j and p fdr 0.05 in both the training and test sets) underwent gene set enrichment analysis.
CpGs Methylation Versus Gene Expression
Because our study envisaged the collection of DNA only, we were unable to assess RNA transcript levels for our mesothelioma cases and related controls. To assess a possible relationship between DM-CpGs and gene expression variations of the corresponding genes, we took advantage of other in-house studies for which whole transcriptome gene expression and DNAm data were available. Data from two sample sets were used: (1) 72 healthy subjects included in a genotype-phenotype correlation study (from here on, Geno-Pheno) described elsewhere for which methylation and gene expression were assessed on DNA and RNA from the same aliquot of peripheral blood mononuclear cells (PBMCs); and (2) 21 normal pleura surgical samples from donors that were subjected to thoracoscopy for conditions different from MPM, belonging to a previous study, for which whole genome methylation and whole transcriptome expression were recently assessed as a pilot study (data not shown). 8, 21 In the two studies, methylation levels were determined by the HumanMethylation450 BeadChip and quality controlled as described in the Supplementary Methods. Gene expression levels were determined by the Illumina HumanHT-12 v4 Expression BeadChip according to manufacturer's instructions (Supplementary Methods). Genes were considered expressed if their probe(s) intensity signal(s) was(were) at least twice the BeadChip background. The relationship between methylation and transcript levels of genes was investigated with a Pearson's correlation test.
DNAm Age estimation and Age Acceleration Indices
DNAm-age was estimated for each subject from DNAm levels on the overall sample according to the method proposed by Horvath et al. 22 Estimated DNAmage was compared with chronological age by the Spearman correlation test. Age acceleration (AA) was calculated as the residuals of the DNAm-age estimate regressed on chronological age in both MPM cases and cancer-free controls: positive AA suggests a biological age older than chronological age, whereas a negative AA suggests that the individual is biologically younger.
Two additional AA indices, intrinsic epigenetic AA (IEAA) and extrinsic epigenetic AA (EEAA), were calculated as well. As reported by Chen et al., 22 EEAA is influenced by blood cell count contribution, whereas IEAA value is only weakly correlated with estimated measures of blood cell counts. The two indices, estimated from DNAm data, are thus indicators of two different cellular ageing processes, one (EEAA) dependent on and the other (IEAA) independent from WBC count. Differences between cases and controls were tested by W test with p 0.05 considered statistically significant, and by a generalized linear models analysis adjusted for sex and asbestos exposure levels.
Results
Sample descriptive statistics are reported in Table 1 . The distribution of subjects' characteristics of cases and controls included in the training set and cases and controls included in the test set is rather homogeneous and comparable: training and test set subjects did not differ by age, tumor histology, smoking habits, exposure dose and source, estimated WBCs percentages (W test), sex, center of recruitment, case-control distribution (chisquare test), except for a difference in B cell distribution in controls between the training and test sets (W test, p ¼ 0.04).
Conversely, when comparing cases versus controls within each of the two sets, cases were exposed to significantly higher cumulative doses of asbestos than controls, and had statistically significant differences in WBC distribution with respect to controls ( Table 1) .
After quality controls on raw DNAm data, 389,147 CpGs were used in the following analyses.
Single-CpGs DMe Analysis
In the training set, 887 CpGs had effect size ! |0.10| at case-control DMe analysis, 884 of them with p fdr < 0.05. Thirteen CpGs were hypermethylated in cases, whereas 871 were hypomethylated (Supplementary Table 1 ). Of the 884 significantly DM-CpGs in the training set, 868 showed significant DMe (p fdr targeted < 0.05) also in the test set with concordant and similar effect sizes (Supplementary Table 1) , and were annotated to 599 genes that were analyzed for pathway enrichment. We found statistically significant enrichment for neutrophil degranulation, innate immune system, and immune system (Supplementary Table 2-A) .
We appraised the huge number of hypomethylated signals (N ¼ 871) identified in the training set, we then posed a more stringent threshold at effect size of less than or equal to -0.15, obtaining a smaller group of 20 hypomethylated CpGs. The resulting DM-CpGs list from the discovery analysis in the training set thus included 20 hypomethylated CpGs with effect size less than or equal to -0.15 and 13 hypermethylated with effect size greater than or equal to 0.10. Checking for strictly replicating signals in the test set, we ended up with seven top DM-CpGs, three hypomethylated CpGs with effect sizes less than or equal to -0.15 in both the training and test sets (genes FOXK1, MYB, and TAF4) and four CpGs hypermethylated with effect sizes greater than or equal to 0.10 in both the training and test sets (genes CXCR6/FYCO1, TAP1, MORC2, and LIME1) ( Table 3) .
We then performed two unsupervised clustering analyses on test set samples to inspect the distribution of cases and controls according to their methylation levels at the DM-CpGs identified in the training set: the first one (Supplementary Fig. 2A ) included the top DM-CpGs, irrespective of strict replication criteria, that is, all the 33 top DM-CpGs identified in the training set; the second one ( Supplementary Fig. 2B ) included only the seven DM-CpGs whose effect sizes strictly replicated in the test set, as described above. Cutting the sample dendrograms at the first node, in both analyses the groups with the most hypomethylated/hypermethylated DM-CpGs included the highest proportion of cases as compared to the other group ( Supplementary Figs. 2A and B) .
The AUC comparison of two models (see Methods) showed a statistically significant improvement in discrimination between cases and controls when including methylation levels into the analysis (Fig. 1) .
A univariate regression analysis in the overall MPM cases (N ¼ 163) was performed to check for a possible relationship between methylation levels at each of the seven DM-CpGs versus tumor histotype, coded as epithelioid, sarcomatoid/fibrous, biphasic/mixed, nondefined, and unknown. Taking epithelioid histotype as the reference one, no clear evidence of methylation differences linked to different histotypes was found, except for the methylation levels of cg08450017 in CXCR6/FYCO1 that were significantly slightly reduced in biphasic/mixed MPMs with respect to epithelioid type (effect size ± SE ¼ -0.05 ± 0.03, p ¼ 0.048).
To assess if smoking habits could modify DNAm profiles at the seven DM-CpGs, we categorized all subjects as current-, former-, and never-smokers, and then performed a multivariate regression analysis in the overall sample (163 MPM cases, 137 controls) with the same model used for the discovery phase adding smoking status as a covariate. No evidence of methylation differences linked to different smoking categories was found for any of the top CpGs, except for the methylation levels of cg00446123 in LIME1 that were List of the top CpGs hypomethylated with effect size less than or equal to -0.15 and hypermethylated with effect size greater than or equal to 0.10 in both the training set and test set (cases versus controls). ID, identification; Chr, chromosome; UCSC, University of California Santa Cruz; fdr, false discovery rate; EWAS, epigenome-wide association study; CpG, cytosine-guanine dinucleotides; MPM, malignant pleural mesothelioma; Eff., effect size.
significantly slightly reduced in ex-smokers with respect to current smokers taken as the reference group (effect size ± SE ¼ -0.034 ± 0.017, p ¼ 0.049). For a subset of cases, for which more detailed clinical information was available, we checked for a possible relationship between methylation levels of the top seven CpGs and time of blood drawing, and clinical TNM staging. Results are reported in the Supplementary Results.
Lastly, the possible relationship between methylation levels and genomic variability was checked for FOXK1, which is located in region 7p22.2 and was found to be associated with MPM in our previous Genome Wide Association Study report and in the companion paper of our collaborators. 9, 23 Results are reported in the Supplementary Results.
Regional DMe Analysis
The A-clustering algorithm identified 24,573 CpGs clusters with correlated methylation levels in the training set and 23,676 in the test set that were tested for DMe between cases and controls. As a first step, we checked for clusters of DM-CpGs around the seven top DM-CpGs identified at the single-CpG analysis and found that five of the seven top DM-CpGs identified at the single CpG analysis were included in CpG clusters DMe between cases and controls ( Table 4) .
As a second step, across the 24,573 CpGs clusters identified in the training set, we looked for DMRs between cases and controls with effect size ! |0.10|, and found 35 DMRs hypomethylated (p fdr < 0.05) in training set cases. Among the 35 regions, the broadest cluster included nine CpGs in the FOXK1 gene around cg04572930 that was the most hypomethylated CpG identified at single-CpG analysis. No region was hypermethylated above the established threshold (effect size ! |0.10|) in cases with respect to controls in the training set.
All of the 35 regions identified in the training set were represented as clusters also in the test set, and all of them showed statistically significant hypomethylation in cases (range: -0.12; -0.07, median: -0.10, p fdr < 0.05) (Supplementary Table 3 ). Restricting the analysis to clusters with effect size less than or equal to -0.10 and p fdr < 0.05 in both the training and test sets (that is, strictly replicating DMRs), 21 regions corresponding to 21 genes were identified. The five regions with more than two CpGs in cluster were noted as top DMRs, and corresponded to the following genes: FOXK1 (nine CpGs), CSTA (four CpGs), ZNF516 (three CpGs), TOLLIP (three CpGs), and TNFAIP6 (three CpGs).
At a gene-set analysis on the 21 DMRs, no statistically significant enriched category r was found. However, considering enriched categories that included more than one gene, we found that the most represented pathways were related to immune systems processes (three categories, five genes in multiple categories), cancer related pathways (five categories, seven genes in multiple categories), and developmental biology (one category, five genes) (Supplementary Table 2B ).
CpGs Methylation Versus Gene Expression
The methylation levels of the seven DM-CpGs and of the 21 CpGs from the regional analysis were correlated with the corresponding gene-expression levels in two a In bold type is the index CpG (i.e., among the 7 top DM-CpGs), and in italics and underlined are CpGs identified also at single-CpGs analysis (i.e., among the 868 DM-CpGs). b this CpG is member of the cluster only in training set. CpG, cystosine-guanine dinucleotides; UCSC, University of California Santa Cruz; Eff., effect size; fdr, false discovery rate; DM, differentially methylated; DMR, differentially methylated region.
separate datasets: one comprising methylation and gene expression data from healthy subjects (Geno-Pheno) PBMCs, and the other one comprising methylation and gene expression data from healthy pleura. In the Geno-Pheno dataset we found no significant correlation between methylation levels and transcript levels in PBMCs for any of the considered CpGs.
In the healthy pleura dataset, cg08450017 in FYCO1, and eight of nine CpGs in the FOXK1 cluster showed a statistical significant correlation between methylation levels and the corresponding gene transcript levels (Table 5) .
DNAm-Age and AA DNAm-age was estimated for each subject from methylation levels in blood cells and showed a strong correlation with chronological age (Spearman's rank correlation rho ¼ 0.80, p < 2.2E-16).
AA 
Discussion
Altered DNAm is frequently observed in cancer, and DNAm profiles of specific genes were already proposed as potential tools for cancer detection, risk prediction, and prognosis. 5 In our study we investigated WBC DNAm profiles in a large series of MPM cases and controls, all of them with quantitative assessment of asbestos exposure, with the aim of identifying molecular hallmarks of MPM in noninvasively collected blood samples from asbestos-exposed subjects. The role of the immune system in cancer is well known, including mesothelioma, and there are evidences that asbestosrelated antigenic overstimulation and ROS oxidation trigger functional changes in WBCs. 24, 25 Moreover, several previous reports, summarized in Table 2 suggest asbestos-induced immune system deregulation, autoimmune response, and functional changes in WBCs putatively linked to MPM occurrence.
The reduction of estimated CD4þ and CD8þ T lymphocytes in MPM cases that we observed in our study suggests a weaker adaptive immune system and is compatible with the possible occurrence of functional changes in cellular subpopulations in MPM. 26 Considering these evidences, we hypothesized that both numerical and functional changes in WBCs might be reflected in methylation changes in MPM cases compared with controls, thus we did not include WBC estimated counts as a covariate in our analyses. In general, WBC model adjustment is meant to control for interindividual variability, which might be essential when healthy subjects are compared, but might introduce biases when analyzing subjects with diseases that trigger immune system response resulting in different cell counts and activation profiles. In our sample, MPM cases showed older WBCs than controls according to epigenetic ageing profiles: the EEAA index, which does not account for differences in WBCs composition, is significantly different between cases and controls, indicating that cases' WBCs are epigenetically older than those of controls. 22 Epigenetic AA was associated with mortality and age-related diseases, and may play a role in MPM too, making it worthy of further investigation. [27] [28] [29] In this study we identified signals of cases versus controls differential DNAm both at single-CpG and regional analyses. The top hypomethylated DM-CpG is located in Forkhead Box K1 (FOXK1), a transcription factor involved in development and metabolism, and Wnt signaling. 30 We found FOXK1 differentially methylated also at regional analysis, with a nine-CpGs cluster hypomethylated in cases. The involvement of FOXK1 in tumor onset and progression was previously reported for colorectal and gastric cancers. 31, 32 It was also recently reported that mammalian target of rapamycin complex (mTORC)-mediated dephosphorylation of FOXK1 transactivates CCL2 gene promoting tumor associated macrophages infiltration in mice, contributing to tumor progression. 33 Moreover, FOXK1 directly interacts with BRCA1-associated protein 1 (BAP1), whose involvement in MPM has been already described. [34] [35] [36] [37] Notably, FOXK1 is located on chromosome 7p22.2, one of the five genomic regions that we previously identified as associated to MPM in a Genome Wide Association Study on Italian samples and that were further replicated in an independent Australian MPM sample. 9 However, no evident relationship between methylation levels and genomic variation at the FOXK1 locus was found, at least for the six single nucleotide polymorphisms (SNPs) for which the genotypes were available in our sample (Supplementary Results).
The most hypermethylated single-CpG signal is located in FYVE and coiled-coil domain containing 1 (FYCO1) gene body, and in the promoter region of C-X-C motif chemokine receptor 6 (CXCR6) gene, which is antisense transcribed to FYCO1 intron 14.
Interestingly, FYCO1 encodes for a putative FOXK1 interactor within the human autophagy network. 38 In the present study, CpGs in FYCO1 and FOXK1 are the only signals whose methylation levels showed significant positive correlation with gene expression levels, as measured in a set of healthy pleura samples.
CXCR6, a T cell chemokine receptor, and its ligand, the chemokine CXCL16, were recently described as markers and promoters of inflammation-associated cancers, such as prostate cancer, and were suggested as mediators of inflammation-related tumorigenesis through direct effects on cancer cell growth and by inducing the migration and proliferation of tumorassociated leukocytes. 39 The same authors reported that the expression of CXCR6/CXCL16 in both cancer cells and adjacent T cells correlated with prostate cancer progression.
Of the 868 DM-CpGs (599 genes) and the 21 DMRs (21 genes), we found several signals in genes belonging to neutrophil degranulation, innate immune system, and immune system reactome pathways. This is not surprising, since we are studying DNAm in WBCs with the purpose to identify relevant changes potentially associated with processes leading to MPM onset.
Among the top signals, three of five hypermethylated DM-CpG, that is, the transporter 1, ATP binding cassette subfamily B member (TAP1), Lck Interacting transmembrane adaptor 1 (LIME1), and C-X-C motif chemokine receptor 6 (CXCR6), as well as three of the top DMRs, that is, cystatin A (CSTA), toll interacting protein (TOLLIP), and TNF alpha induced protein 6 (TNFAIP6) have a role in the immune system and/or inflammationrelated processes. [40] [41] [42] [43] Taken together, our findings of DMe in WBCs suggest that DNAm changes in the immune system components may play a role in or may be a consequence of the oncogenic process triggered by asbestos exposure. However, a major limitation to the functional interpretation of our results is that all MPM subjects have already developed the disease at recruitment: thus, our findings likely reflect the disease status rather than being causal factors in the dynamic processes leading to MPM onset. Cases were enrolled at MPM diagnosis, when the tumor was already in place, so we cannot exclude a reverse causality bias, and we are thus unable to establish whether methylation changes are associated with the carcinogenic process or are consequence of the disease.
Another limitation is the unavailability of MPM tissue from the same subjects, which also poses major constrains to the functional interpretation of our findings and prevents the possibility to compare DNAm profiles in blood cells and in tissue samples or pleural effusions of MPM cases. Although we could not prove, in the context of this study, whether or not DNA methylation profiles in blood reflect the status of the tumor, in our view they may be assumed as biomarkers of actual disease (given the cross-sectional nature of the study). As a matter of fact, notwithstanding the above limitations, the discrimination between MPM cases and non-MPM asbestos-exposed controls improved when DNAm levels were considered together with asbestos exposure levels.
The significant difference in degree of asbestos exposure between case and control is a critical issue in verifying these signatures as markers for the early detection of MPM in asbestos-exposed subjects. For this reason, we corrected our analyses for individual levels of asbestos exposure, taking advantage of well-recorded asbestos exposure information, and thus we identified DNA methylation biomarkers which are not directly associated to asbestos exposure. Since it is not always possible to accurately quantify asbestos doses for exposed subjects, it is important to develop tools to confidently identify those asbestos-exposed subjects who are prone to MPM occurrence also when it is not possible to assess the cumulative dose they have been exposed to. The here-reported evidences of detectable methylation differences in asbestos-exposed subjects with and without MPM provide the rationale to search for possible DNAm early changes associated with MPM development. Monitoring methylation changes on the trajectory to the disease, from asbestos exposure to overt MPM diagnosis, is a necessary task for the identification of early epigenetic change biomarkers related to MPM to be used for the monitoring of asbestos-exposed subjects. MPM is characterized by the accumulation and persistence of asbestos fibers in the lungs, leading to a long latency period before clear clinical signs of the tumor are detectable. As of today, early MPM detection is still poor. Serum biomarkers such as mesothelin, megakaryocyte potentiating factors, osteopontin, CYFRA21-1, and fibulin-3 were tested for early MPM diagnosis with limited results and, so far, neither radiologic nor biochemical screening studies have proven useful. In our view, progressive changes in WBCs' DNAm levels may provide a tool to monitor progressive alterations in the immune system of asbestos-exposed subjects, potentially related to MPM development (Fig. 2) . 44 Further studies in prospectively collected cohorts of asbestos-exposed subjects with blood sampling at multiple points across time will be needed to clarify if, and to what extent, methylation changes progress across time towards the tumor onset. This is particularly important because, despite the banishment of asbestos itself and asbestoscontaining materials in several countries, individuals who have already been exposed will remain at risk of MPM, whose incidence is just expected to peak in the next years in European countries.
Overall, our study identified signatures of DMe in DNA from whole blood between asbestos exposed MPM Figure 2 . Hypotheses generation and rationale for future studies following the identification of differential methylation between asbestos exposed subjects with and without malignant pleural mesothelioma (MPM). CpG, cytosine-guanine dinucleotides.
cases and non-MPM controls, both at single-CpG and at genomic region levels. We suggest that differential methylation patterns of selected CpGs in DNA from WBCs may aid in discriminating MPM cases from asbestos-exposed non-MPM subjects and can be used to further improve MPM risk estimation is subjects occupationally and/or environmentally exposed to asbestos.
